Livforsakringsbolaget Skandia’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $331K | Hold |
1,000
| – | – | 0.01% | 268 |
|
|
2025
Q4 | $398K | Hold |
1,000
| – | – | 0.02% | 250 |
|
|
2025
Q3 | $455K | Hold |
1,000
| – | – | 0.02% | 256 |
|
|
2025
Q2 | $325K | Hold |
1,000
| – | – | 0.01% | 309 |
|
|
2025
Q1 | $270K | Hold |
1,000
| – | – | 0.02% | 331 |
|
|
2024
Q4 | $235K | Hold |
1,000
| – | – | 0.01% | 366 |
|
|
2024
Q3 | $275K | Buy |
1,000
+800
| +400% | +$208K | 0.01% | 357 |
|
|
2024
Q2 | $48.6K | Hold |
200
| – | – | ﹤0.01% | 389 |
|
|
2024
Q1 | $29.9K | Hold |
200
| – | – | ﹤0.01% | 462 |
|
|
2023
Q4 | $38.3K | Hold |
200
| – | – | ﹤0.01% | 426 |
|
|
2023
Q3 | $35.4K | Hold |
200
| – | – | ﹤0.01% | 371 |
|
|
2023
Q2 | $38K | Hold |
200
| – | – | ﹤0.01% | 374 |
|
|
2023
Q1 | $40.1K | Hold |
200
| – | – | ﹤0.01% | 366 |
|
|
2022
Q4 | $47.5K | Hold |
200
| – | – | 0.01% | 335 |
|
|
2022
Q3 | $40K | Sell |
200
-600
| -75% | -$114K | ﹤0.01% | 350 |
|
|
2022
Q2 | $117K | Sell |
800
-1,100
| -58% | -$156K | 0.01% | 435 |
|
|
2022
Q1 | $310K | Hold |
1,900
| – | – | 0.02% | 362 |
|
|
2021
Q4 | $322K | Hold |
1,900
| – | – | 0.02% | 379 |
|
|
2021
Q3 | $359K | Hold |
1,900
| – | – | 0.02% | 396 |
|
|
2021
Q2 | $322K | Buy |
1,900
+600
| +46% | +$87.9K | 0.02% | 462 |
|
|
2021
Q1 | $184K | Hold |
1,300
| – | – | 0.01% | 482 |
|
|
2020
Q4 | $169K | Hold |
1,300
| – | – | 0.01% | 475 |
|
|
2020
Q3 | $189K | Hold |
1,300
| – | – | 0.02% | 401 |
|
|
2020
Q2 | $193K | Hold |
1,300
| – | – | 0.02% | 394 |
|
|
2020
Q1 | $142K | Hold |
1,300
| – | – | 0.02% | 403 |
|
|
2019
Q4 | $150K | Buy |
1,300
+500
| +63% | +$49.8K | 0.02% | 409 |
|
|
2019
Q3 | $64K | Hold |
800
| – | – | 0.01% | 588 |
|
|
2019
Q2 | $58K | Hold |
800
| – | – | 0.01% | 587 |
|
|
2019
Q1 | $75K | Hold |
800
| – | – | 0.01% | 551 |
|
|
2018
Q4 | $58K | Hold |
800
| – | – | 0.01% | 568 |
|
|
2018
Q3 | $70K | Sell |
800
-1,200
| -60% | -$121K | 0.01% | 620 |
|
|
2018
Q2 | $197K | Hold |
2,000
| – | – | 0.02% | 509 |
|
|
2018
Q1 | $238K | Buy |
2,000
+700
| +54% | +$90.2K | 0.02% | 456 |
|
|
2017
Q4 | $165K | Buy |
+1,300
| New | +$163K | 0.02% | 534 |
|
|
2016
Q4 | – | Sell |
-15,100
| Closed | -$294K | – | 689 |
|
|
2016
Q3 | $294K | Buy |
15,100
+7,800
| +107% | +$550K | 0.01% | 657 |
|
|
2016
Q2 | $405K | Hold |
7,300
| – | – | 0.02% | 640 |
|
|
2016
Q1 | $458K | Hold |
7,300
| – | – | 0.02% | 626 |
|
|
2015
Q4 | $687K | Hold |
7,300
| – | – | 0.03% | 530 |
|
|
2015
Q3 | $587K | Hold |
7,300
| – | – | 0.03% | 558 |
|
|
2015
Q2 | $875K | Buy |
+7,300
| New | +$872K | 0.04% | 500 |
|
Other funds holding ALNY
VPM
VCM
Livforsakringsbolaget Skandia's ALNY Position: Q1 2026 in Review
Livforsakringsbolaget Skandia held its Alnylam Pharmaceuticals (ALNY) position steady in Q1 2026 at 1,000 shares worth $331K. The position accounts for 0.01% of the portfolio, ranked #268.
Livforsakringsbolaget Skandia first reported a position in ALNY in Q2 2015 and has held it in 40 quarters since. The position peaked at $875K in Q2 2015. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Livforsakringsbolaget Skandia held 1,000 shares of Alnylam Pharmaceuticals worth $331K as of Q1 2026.
- Livforsakringsbolaget Skandia left its Alnylam Pharmaceuticals share count unchanged in Q1 2026.
- Alnylam Pharmaceuticals made up 0.01% of Livforsakringsbolaget Skandia's portfolio in Q1 2026, its #268 holding.
- Livforsakringsbolaget Skandia first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 40 quarters since.
- Livforsakringsbolaget Skandia's Alnylam Pharmaceuticals position peaked at $875K in Q2 2015.
- 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Livforsakringsbolaget Skandia's 13F filing for Q1 2026, filed 5 May 2026.